{"retracted":false,"update":{"timestamp":1440115200000,"doi":"10.1371/journal.pone.0136515","type":"correction"},"doi":"10.1371/journal.pone.0133968","journal":"PLOS ONE","publisher":"Public Library of Science (PLoS)","title":"Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA"}
